Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Consolidated Statements Of Operations    
Revenues
Operating expenses:    
Amortization & depreciation 454
General and administrative 396,143 446,983
Total operating expenses 396,143 447,437
Loss from operations (396,143) (447,437)
Other income (expense):    
Gain/(Loss) on fair value adjustment - derivatives 25,456
Gain on debt reversal 485
Interest expense (218,339) (251,500)
Interest expense - beneficial conversion feature 15,250 (23,750)
Total other income (expense) (203,089) (249,309)
Loss before provision for income taxes (599,232) (696,746)
Net loss (599,232) (696,746)
Less: Net loss attributable to noncontrolling interest 4,102 5,012
Net loss attributable to TranBioTec, Inc. $ (595,130) $ (691,734)
Net loss per share    
(Basic and fully diluted) $ (0.01) $ (0.01)
Weighted average number of common shares outstanding 67,320,740 59,261,114